We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL).
- Authors
Lee, H.; Choi, M.; Siddiqi, T.; Rhodes, J.; Wierda, W.; Isufi, I.; Tuscano, J.; Lamanna, N.; Subbiah, S.; Koff, J.; Leslie, L.; Goldenberg, A.; Chung, G.; Breitmeyer, J.; Yazji, S.; Shih, T.; Wang, M.; Jamieson, C.; Kipps, T.
- Abstract
B Background: b Zilovertamab (Zilo) is a humanized monoclonal antibody that inhibits the tumor promoting activity of the cancer stem cell receptor, ROR1, which is highly expressed in many hematologic malignancies but not on normal adult tissues. B Safety in MCL and CLL: b The most frequent (>=30%) treatment emergent adverse events (TEAEs) for all MCL & CLL pts on Zilo+Ibr ( I n i = 85) were diarrhea & fatigue (45.9%), contusion (38.8%) and cough (30.6%).
- Subjects
MUCOSA-associated lymphoid tissue lymphoma; MANTLE cell lymphoma; CHRONIC lymphocytic leukemia; NURSING consultants
- Publication
Hematological Oncology, 2023, Vol 41, p587
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_440